Telix Pharmaceuticals a Melbourne, Australia-based biopharmaceutical company, acquired Optimal Tracers, an Indianapolis, IN-based radiochemistry development company.
The amount of the deal was not disclosed.
With the acquisition, Telix Pharmaceuticals will bolster its in-house radiochemistry development capability, by establishing a U.S.-based laboratory and production footprint for clinical trial doses.
Led by CEO Ruth Tesar, Optimal Tracers is a division of Northern California PET Imaging Center, a community based not for profit business providing clinical and clinical trial imaging and services to the Northern California region. The company provides manufacturing and development radiochemistry services in support of academic and pharmaceutical research activities.
Led by CEO Christian Behrenbruch, Telix Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. The company is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange.
Its lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),[1] and by the Australian Therapeutic Goods Administration (TGA),[2] and by Health Canada.[3]